⌘K (Command K) to search

Sign in Sign up free

Insider · CIK 0001806763

Cross John Harry III

Reports to the SEC for 2 companies · SOUTH SAN FRANCISCO, CA

Transactions

6

Companies

2

Filings

6

CIK

0001806763

Forms 4 and 5

Insider transactions

6 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-03-07	SNTISenti Biosciences Holdings, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+174K sh	—	—	174,200
2023-12-11	Sonnet BioTherapeutics Holdings, Inc.A Award	Chief Financial Officer	AAward	−1,452 sh	—	—	1,588
2023-02-06	Sonnet BioTherapeutics Holdings, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−1,960 sh	$1.06	−$2,077.6	23,927
2022-12-14	Sonnet BioTherapeutics Holdings, Inc.A Award	Chief Financial Officer	AAward	+15.5K sh	—	—	160,684
2021-12-15	Sonnet BioTherapeutics Holdings, Inc.A Award	Chief Financial Officer	AAward	+67K sh	—	—	145,165
2020-07-02	Sonnet BioTherapeutics Holdings, Inc.A Award	Chief Financial Officer	AAward	+78.2K sh	—	—	78,214

Recent filings

6

Accepted (ET)
Mar 114
Cross John Harry III0001854270-25-000026
SEC(opens sec.gov)
Dec 54
Cross John Harry III0001493152-24-048950
SEC(opens sec.gov)
Feb 174
Cross John Harry III0001493152-23-005464
SEC(opens sec.gov)
Dec 224
Cross John Harry III0001493152-22-036315
SEC(opens sec.gov)
Apr 84
Cross John Harry III0001493152-22-009485
SEC(opens sec.gov)
Jul 24
Cross John Harry III0001493152-20-012570
SEC(opens sec.gov)

Companies

2

Address

C/O SENTI BIOSCIENCES, INC. 2 CORPORATE DRIVE FIRST FLOOR

SOUTH SAN FRANCISCO, CA, 94080